- This study found that apixaban has lower absolute risks compared to other oral anticoagulants (OACs) for patients with dementia and atrial fibrillation (AF).
- This study aimed to expand on the limited data on the efficacy and safety of OACs in the population of older adults with dementia and AF.
- There were 1,160,462 older adults with AF recruited for the study. The main exposures analyzed were apixaban, rivaroxaban, dabigatran, and warfarin.
- Participants with dementia had higher composite endpoint rates than apixaban users, although benefits associated with apixaban were similar in all comparisons, with a more distinct pattern for major bleeding than for ischemic stroke.